DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path
We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1] The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies. Compared to 2015, trial numbers have steadily Continue reading DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path
